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Joseph S. Tash, PhD,
Director, Interdisciplinary Center for Male 
Contraceptive Research & Drug Development
University of Kansas Medical Center
World Health Organization 
Worldwide Reproductive Statistics*
 122 million planned pregnancies per year
 87 million unintended pregnancies per year (42% 
of all pregnancies)
The Magnitude of the Need for New Alternatives in 
Family Planning
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*http://www.who.int/whr/2005/chapter3/en/index3.html
 46 million pregnancies are terminated by abortion 
per year
 World Health Organization, National Institutes of 
Health, and Institute of Medicine have all 
stressed the need to develop new male 
contraceptive methods
Interdisciplinary and Multi-Institutional 
Components of Male Contraceptive 
Development
 Reproductive biology (KUMC)
 Medicinal chemistry (U. Minn, KU)
 Molecular genetics (KUMC, Moffitt, UMDNJ)
Proteomics 
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 (KU, KUMC)
 Structural biology/X-ray crystallography (Moffitt, 
UMDNJ)
 High throughput screening (HTS) (U. Minn, KU)
 Pharmacology/toxicology (KU, IAMI)
 Clinical/Urology (KUMC)
KUMC NIH U54 
Male Contraceptive Center Organization
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Chronology of Gamendazole 
Discovery and Development 
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1969:  I decided to devote my career towards developing a male 
contraceptive
1969-2000: Researched basic biology of male reproduction including sperm 
function and testis function: search for targets and mechanism that could 
be used to develop a male contraceptive
2000:  NIH offers contract RFA to Design an  Test Novel Non-
Hormonal Reversible Male Contraceptive Agents
Chronology of Gamendazole 
Discovery and Development 
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2002: RC-MC-110 (gamendazole) synthesized after several dozen SAR 
(structure-activity relationship) synthesis rounds
Chronology of Gamendazole 
Discovery and Development 
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2004: US Patent filed to protect IP soon after gaining proof of concept (POC)
Chronology of Gamendazole 
Discovery and Development 
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2005: License agreement signed 
(too early in process, later disclosures from licensee were disturbing)
Chronology of Gamendazole 
Discovery and Development 
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2007: Licensee pulls a product that was not disclosed to be in clinical trials, 
their stock values plummet preventing their meeting milestones,
license is terminated. 
Chronology of Gamendazole 
Discovery and Development 
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2009: US patent issued for Gamendazole and analogues issued: 
composition of matter, synthesis, use as contraceptives
Chronology of Gamendazole 
Discovery and Development 
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2010: First non-human primate POC study started:
So far proven safe and reversible inhibition of spermatogenesis observed. 
Additional dose finding planned.
ONPRC Pilot Project: 
Reversible Inhibition of Spermatogenesis in 
Nonhuman Primates by Novel Non-hormonal 
Contraceptive Agent, H2-Gamendazole
Joseph Tash, Ph.D. Principal Investigator, KUMC
Contraception & Reproductive Health Branch, 
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NICHD, NIH U54 HD-055763 (JST)
Mary B. Zelinski, Co-Investigator, ONPRC
Gunda Georg, Ph.D.
Institute for Therapeutics Discovery & Development, University of Minnesota
Scott Weir, Pharm. D., Ph.D.
Melinda Broward, M.S.
Cancer Center, University of Kansas
Reversible Inhibition of Sperm Production in
First Non-Human Primate* by Single Oral 
Dose of H2-Gamendazole
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13*Study will last 12 weeks in each of 3 monkeys at 2 different oral doses
Day post treatment
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Chronology of Gamendazole 
Discovery and Development 
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2010: Bill and Melinda Gates Foundation convenes “Experts in Contraception” 
meeting to define strategies to get contraceptive in use SSA & SA
H2-gamendazole placed on the map.
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Male Contraceptive 
Drug Development Program:
From Target Validation through Identification of Development Candidate
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IND Pre-Clinical and First in Human Trials:
POC in Males Undergoing Elective Vasectomy
18
KU-AS-272 As a Single Dose Non-Surgical  
Sterilant for Male and Female Dogs and Cats and 
Feral Animals
Female MiceMale Rats
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Project Timeline for KU-AS-272 as Single Dose 
Non-Hormonal Sterilant for Male & Female Dogs & Cats
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Conclusions
 Collaboration is essential
 Employ the knowledge of experts outside your 
own comfort zone or knowledge base
 Find alternatives, most leads fail along the way
 Protect IP early, be as broad as possible
21
 Don’t license too early, later is more attractive
 Accept that as things move along the pipeline 
they seem to move slower
 Constantly strive towards your goal, but be 
flexible along the way
Male Contraceptive Collaborators (1)
 Tash lab: Lesya Holets, Ph.D., Julie Cotitta, Vijayalaxmi Gupta, Ph.D., 
Anne Grissell, Brian Kern, S. Kendall Smith, Jennifer Hughes, Jackie Huff, 
Aneesha Garry, Stacy Wolfe, Brady Timmerberg, Michael J.  Wulser, 
Sotirios-E. Macheras, Adam Gregg, Melissa K. Emerson, Brent Burroughs, 
Kimberly Pickens (post doc, medical students, and technicians) 
 Georg lab (U.Minn): Gunda Georg, Derek Hook, Ramappa Chakrasali, 
Sudhakar R. Jakkaraj, Subhashree Rangarajan, Dinah Dutta, Xingxian Gu
(U54, NIH contract, medicinal chemistry)
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 Heckert lab (KUMC): Leslie L. Heckert, Kaori Hornbaker (U54, Sertoli
cells, rt-PCR)
 Blanco lab (KUMC): Gustavo Blanco (U54)
 Kinzy lab (UMDNJ): Terri Goss Kinzy, Jenna Hutton, Sedide B. Ozturk 
(EEF1A1)
 Schönbrunn lab (Moffitt Cancer Center): Ernst Schönbrunn, Andreas 
Beckerman (U54, NIH contract, HTS, protein cloning/expression, x-ray 
crystallography)
 Blagg lab (KU-Lawrence): Brian S. J. Blagg, M. Kyle Hadden (Hsp90)
Male Contraceptive Collaborators (2)
 BIOQUAL: Barbara Attardi, Sheri A. Hild, Janet Burgenson, David Gropp, 
Jessica Luke, Margaret Krol, Trung Pham, Bruce Till (NIH Mating trials, 
Sertoli cells, endocrinology)
 KUMC: Paul Terranova, Ajay Nangia, M.D., George Enders, Kathy Roby 
(translational research support, pathology, ID8)
 KU/KUMC IAMI: Scott Weir, Melinda Broward, Roger Rajewski (drug 
development, pharmacokinetics, formulation)
 KU Biochemical Research Service Lab: Michael Alterman, Todd Williams 
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(MALDI-TOF, MS, proteomics)
 KUMC Microarray Core: Clark Bloomer, Stan Svojanovsky
 Imaging Core: William Kinsey, Stan Fernald (U54, CRS) 
 NIH: Hyun K. Kim, Diana Blithe, June Lee, Contraception & Reproductive 
Health Branch, NICHD
 Supported by: NIH U54 HD-055763 (to JST), NIH N01 HD1-3313 (to 
GIG), U54 HD33994 Center for Reproductive Sciences (Specialized 
Cooperative Centers Program in Reproductive Research, SCCPRR), 
N01-HD-2-3338 (to BIOQUAL Inc.)
Thanks!
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RC-MC-110 passes Ames test, first animal testing begins
Chronology of Gamendazole 
Discovery and Development 
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Proof of concept (POC) as reversible male contraceptive achieved
Chronology of Gamendazole 
Discovery and Development 
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H2-gamendazole synthesized and testing started
Chronology of Gamendazole 
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Based on goal of single dose 100% efficacy AND 100% reversibility
NIH and we agree that observed 100% efficacy with 67% reversibility isn’t good enough.
We start multiple low dose range finding studies.
Chronology of Gamendazole 
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Collaboration with Kidney Institute yields 
POC gamendazole analogues as treatment for Polycystic Kidney Disease,
Divisional patent filed, divisional patent for female contraceptive agents added
Chronology of Gamendazole 
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H2-gamendazole and gamendazole pass hERG test
Chronology of Gamendazole 
Discovery and Development 
32
Critical POC toxicology will start at CRO (IAMI funded)
Chronology of Gamendazole 
Discovery and Development 
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QWBA will start at CRO (IAMI funded)
Chronology of Gamendazole 
Discovery and Development 
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2010: NIH to start new mating trials with single weekly 4 week dosing regimen
